Jeff Yass’s Larimar Therapeutics LRMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $441K | Buy |
144,428
+4,368
| +3% | +$17.3K | ﹤0.01% | 10201 |
|
|
2026
Q1 | $630K | Sell |
140,060
-112,723
| -45% | -$451K | ﹤0.01% | 9067 |
|
|
2025
Q4 | $963K | Buy |
252,783
+181,360
| +254% | +$705K | ﹤0.01% | 7280 |
|
|
2025
Q3 | $231K | Sell |
71,423
-178,872
| -71% | -$671K | ﹤0.01% | 10677 |
|
|
2025
Q2 | $723K | Buy |
250,295
+88,393
| +55% | +$205K | ﹤0.01% | 8280 |
|
|
2025
Q1 | $348K | Buy |
161,902
+94,323
| +140% | +$298K | ﹤0.01% | 9727 |
|
|
2024
Q4 | $262K | Buy |
67,579
+46,722
| +224% | +$308K | ﹤0.01% | 10126 |
|
|
2024
Q3 | $137K | Sell |
20,857
-31,123
| -60% | -$250K | ﹤0.01% | 10824 |
|
|
2024
Q2 | $377K | Sell |
51,980
-6,142
| -11% | -$47K | ﹤0.01% | 8938 |
|
|
2024
Q1 | $441K | Buy |
58,122
+47,747
| +460% | +$372K | ﹤0.01% | 8815 |
|
|
2023
Q4 | $47.2K | Buy |
+10,375
| New | +$35K | ﹤0.01% | 11735 |
|
|
2023
Q3 | – | Sell |
-12,818
| Closed | -$48.5K | – | 12542 |
|
|
2023
Q2 | $40.1K | Sell |
12,818
-167,135
| -93% | -$682K | ﹤0.01% | 11420 |
|
|
2023
Q1 | $815K | Buy |
+179,953
| New | +$940K | ﹤0.01% | 7358 |
|
|
2022
Q4 | – | Sell |
-15,709
| Closed | -$50K | – | 13138 |
|
|
2022
Q3 | $50K | Buy |
+15,709
| New | +$39.4K | ﹤0.01% | 12202 |
|
|
2022
Q2 | – | Sell |
-55,366
| Closed | -$224K | – | 13506 |
|
|
2022
Q1 | $224K | Sell |
55,366
-43,974
| -44% | -$288K | ﹤0.01% | 10965 |
|
|
2021
Q4 | $1.07M | Buy |
99,340
+29,523
| +42% | +$328K | ﹤0.01% | 7118 |
|
|
2021
Q3 | $805K | Buy |
+69,817
| New | +$838K | ﹤0.01% | 8114 |
|
|
2021
Q2 | – | Sell |
-18,810
| Closed | -$275K | – | 12963 |
|
|
2021
Q1 | $275K | Buy |
+18,810
| New | +$342K | ﹤0.01% | 10782 |
|
|
2018
Q2 | – | Sell |
-8,520
| Closed | -$724K | – | 10041 |
|
|
2018
Q1 | $762K | Buy |
8,520
+7,452
| +698% | +$632K | ﹤0.01% | 5784 |
|
|
2017
Q4 | $59K | Buy |
+1,068
| New | +$48.1K | ﹤0.01% | 8868 |
|
|
2017
Q3 | – | Sell |
-6,672
| Closed | -$281K | – | 9277 |
|
|
2017
Q2 | $281K | Buy |
6,672
+5,795
| +661% | +$296K | ﹤0.01% | 7699 |
|
|
2017
Q1 | $49K | Sell |
877
-2,646
| -75% | -$131K | ﹤0.01% | 8595 |
|
|
2016
Q4 | $134K | Buy |
3,523
+1,260
| +56% | +$51.1K | ﹤0.01% | 8925 |
|
|
2016
Q3 | $90K | Buy |
2,263
+493
| +28% | +$22.4K | ﹤0.01% | 7977 |
|
|
2016
Q2 | $127K | Sell |
1,770
-3,380
| -66% | -$267K | ﹤0.01% | 7907 |
|
|
2016
Q1 | $413K | Sell |
5,150
-1,871
| -27% | -$148K | ﹤0.01% | 6729 |
|
|
2015
Q4 | $530K | Buy |
7,021
+3,661
| +109% | +$588K | ﹤0.01% | 6650 |
|
|
2015
Q3 | $1.29M | Buy |
3,360
+2,678
| +393% | +$1.21M | ﹤0.01% | 5160 |
|
|
2015
Q2 | $283K | Sell |
682
-14
| -2% | -$5.86K | ﹤0.01% | 8637 |
|
|
2015
Q1 | $331K | Buy |
+696
| New | +$330K | ﹤0.01% | 7792 |
|
Other funds holding LRMR
DM
BOCH
DCM
DCM
RI
DCM
Jeff Yass's LRMR Position: Q2 2026 in Review
Jeff Yass increased its Larimar Therapeutics (LRMR) stake by 3.1% in Q2 2026, buying an estimated $17.3K and bringing the position to 144,428 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #10201.
Jeff Yass first reported a position in LRMR in Q1 2015 and has held it in 30 quarters since. The position peaked at $1.29M in Q3 2015. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.
- Jeff Yass held 144,428 shares of Larimar Therapeutics worth $441K as of Q2 2026.
- Jeff Yass bought 4,368 Larimar Therapeutics shares in Q2 2026, an estimated $17.3K.
- Larimar Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10201 holding.
- Jeff Yass first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 30 quarters since.
- Jeff Yass's Larimar Therapeutics position peaked at $1.29M in Q3 2015.
- 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.